• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

    9.640 +2.210 (+29.74%)
    Streaming Delayed Price Updated: 12:53 PM EST, Feb 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 28,870,203
    Open 9.835
    Bid (Size) 9.630 (200)
    Ask (Size) 9.640 (500)
    Prev. Close 7.430
    Today's Range 9.120 - 10.29
    52wk Range 4.155 - 9.840
    Shares Outstanding 133,976,538
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Tuesday's session: top gainers and losers ↗
    Via Chartmill
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill

    Performance

    YTD
    +62.3%
    +62.3%
    1 Month
    +29.4%
    +29.4%
    3 Month
    +57.5%
    +57.5%
    6 Month
    +120.1%
    +120.1%
    1 Year
    +1.8%
    +1.8%

    More News

    Read More
    Which stocks are moving before the opening bell on Tuesday? ↗
    Via Chartmill
    News headline image
    VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗
    Via Stocktwits
    Vir Biotechnology Inc (NASDAQ:VIR) Reports Q4 2025 Revenue Beat and Major Pipeline Updates ↗
    Via Chartmill
    Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown ↗
    Via Stocktwits
    News headline image
    Earnings Scheduled For November 5, 2025 ↗
    Via Benzinga
    News headline image
    Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? ↗
    Via Stocktwits
    Topics Earnings
    News headline image
    Vir Biotechnology (VIR) Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Is Alnylam Pharmaceuticals a Millionaire Maker? ↗
    Via The Motley Fool
    News headline image
    Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025
    From Vir Biotechnology, Inc.
    Via Business Wire
    News headline image
    This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗
    Via Benzinga

    Frequently Asked Questions

    Is Vir Biotechnology, Inc. - Common Stock publicly traded?
    Yes, Vir Biotechnology, Inc. - Common Stock is publicly traded.
    What exchange does Vir Biotechnology, Inc. - Common Stock trade on?
    Vir Biotechnology, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Vir Biotechnology, Inc. - Common Stock?
    The ticker symbol for Vir Biotechnology, Inc. - Common Stock is VIR on the Nasdaq Stock Market
    What is the current price of Vir Biotechnology, Inc. - Common Stock?
    The current price of Vir Biotechnology, Inc. - Common Stock is 9.640
    When was Vir Biotechnology, Inc. - Common Stock last traded?
    The last trade of Vir Biotechnology, Inc. - Common Stock was at 02/24/26 12:53 PM ET
    What is the market capitalization of Vir Biotechnology, Inc. - Common Stock?
    The market capitalization of Vir Biotechnology, Inc. - Common Stock is 1.29B
    How many shares of Vir Biotechnology, Inc. - Common Stock are outstanding?
    Vir Biotechnology, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.